Get the Stockscreener App
85.94
0.47%
-0.41
After Hours:
85.94
Overview
News
Price History
Option Chain
Financials
Why ALC Down?
Discussions
Forecast
Dividend History
Alcon Inc stock is traded at $85.94, with a volume of 2.14M.
It is down -0.47% in the last 24 hours and down -11.96% over the past month.
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
See More
Previous Close:
$86.35
Open:
$87.31
24h Volume:
2.14M
Relative Volume:
1.25
Market Cap:
$42.51B
Revenue:
$9.93B
Net Income/Loss:
$1.12B
P/E Ratio:
38.20
EPS:
2.25
Net Cash Flow:
$1.58B
1W Performance:
-0.67%
1M Performance:
-11.96%
6M Performance:
-3.28%
1Y Performance:
-2.73%
1-Day Range:
$85.05
$87.32
1-Week Range:
$84.94
$87.64
52-Week Range:
$80.48
$101.10
Alcon Inc Stock (ALC) Company Profile
Name
Alcon Inc
Sector
Industry
Phone
-
Address
-
Compare ALC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALC
Alcon Inc
|
85.94 | 42.61B | 9.93B | 1.12B | 1.58B | 2.25 |
|
ISRG
Intuitive Surgical Inc
|
552.34 | 194.50B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
172.59 | 49.39B | 20.87B | 1.50B | 2.59B | 5.24 |
|
RMD
Resmed Inc
|
244.79 | 36.00B | 5.02B | 1.31B | 1.56B | 8.91 |
|
BAX
Baxter International Inc
|
30.50 | 15.53B | 11.89B | -560.00M | 191.00M | -1.10 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-20-25 | Downgrade | Deutsche Bank | Buy → Hold |
| May-14-25 | Reiterated | BTIG Research | Buy |
| Mar-28-25 | Reiterated | Needham | Buy |
| Mar-25-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-24-25 | Reiterated | Needham | Buy |
| Jan-10-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Dec-17-24 | Reiterated | Needham | Buy |
| Nov-12-24 | Reiterated | Needham | Buy |
| Oct-10-24 | Upgrade | Redburn Atlantic | Sell → Neutral |
| Sep-10-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-15-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| May-15-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-10-24 | Initiated | Goldman | Buy |
| Mar-14-24 | Initiated | RBC Capital Mkts | Sector Perform |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Jan-23-24 | Initiated | Bernstein | Outperform |
| Dec-18-23 | Downgrade | Redburn Atlantic | Neutral → Sell |
| Dec-12-23 | Initiated | Stifel | Buy |
| Dec-04-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Aug-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| May-10-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-01-23 | Upgrade | Societe Generale | Sell → Hold |
| Dec-22-22 | Initiated | Mizuho | Buy |
| Nov-17-22 | Downgrade | Societe Generale | Hold → Sell |
| Aug-11-22 | Downgrade | Societe Generale | Buy → Hold |
| May-13-22 | Resumed | Credit Suisse | Outperform |
| May-12-22 | Upgrade | Stephens | Equal-Weight → Overweight |
| Apr-08-22 | Initiated | Needham | Buy |
| Mar-11-22 | Initiated | BofA Securities | Buy |
| Jan-18-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jan-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-01-21 | Initiated | Oppenheimer | Perform |
| Jul-14-21 | Initiated | Deutsche Bank | Buy |
| May-06-21 | Upgrade | Citigroup | Sell → Neutral |
| Mar-22-21 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-12-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-06-20 | Downgrade | Citigroup | Neutral → Sell |
| Jul-06-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-08-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-26-20 | Upgrade | Argus | Hold → Buy |
| Mar-24-20 | Upgrade | Societe Generale | Sell → Hold |
| Mar-13-20 | Upgrade | UBS | Neutral → Buy |
| Mar-05-20 | Initiated | Citigroup | Neutral |
| Feb-26-20 | Upgrade | Berenberg | Hold → Buy |
| Jan-08-20 | Initiated | Argus | Hold |
| Oct-29-19 | Initiated | Stephens | Equal-Weight |
| Aug-21-19 | Reiterated | BofA/Merrill | Neutral |
| Jun-24-19 | Initiated | SVB Leerink | Mkt Perform |
| Jun-14-19 | Initiated | BTIG Research | Neutral |
| May-10-19 | Initiated | Robert W. Baird | Outperform |
| May-02-19 | Initiated | Credit Suisse | Outperform |
View All
Alcon Inc Stock (ALC) Latest News
Alcon gains FDA approval of Tryptyr in DED - The Pharma Letter
Citi maintains Buy on Alcon, price target CHF99 after FDA nod - Investing.com India
Alcon Inc. (ALC)’s TRYPTYR Wins FDA Nod for Dry Eye Disease - MSN
FDA Approves Alcon’s Tryptyr for Dry Eye Disease - Managed Healthcare Executive
Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019 - Benzinga
Alcon Stock Rises Following the FDA Approval of TRYPTYR - MSN
US FDA approves Alcon's new dry-eye drug - Reuters
FDA approves Alcon’s Tryptyr (AR-15512) for signs and symptoms of dry eye disease - Ophthalmology Times
Alcon up 4% as FDA approves Tryptyr drops for dry eye - MSN
FDA approves Alcon’s TRYPTYR for Dry Eye Disease treatment By Investing.com - Investing.com South Africa
BTIG maintains Alcon $99 target, upbeat on TRYPTYR launch - Investing.com
US FDA Approves Alcon's Dry Eye Disease Treatment - marketscreener.com
US FDA approves Alcon’s new dry-eye drug - The Mighty 790 KFGO
Alcon (ALC) Gains FDA Approval for Innovative Dry Eye Treatment - GuruFocus
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic s - GuruFocus
Alcon (ALC) Gains FDA Nod for Innovative Dry Eye Treatment | ALC Stock News - GuruFocus
FDA approves Alcon’s TRYPTYR for Dry Eye Disease treatment - Investing.com
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease - marketscreener.com
Gordon Schanzlin New Vision Institute First in Region to Offer Groundbreaking Alcon Sitemap Technology for Personalized Vision Correction - GlobeNewswire Inc.
BTIG maintains Alcon stock Buy rating, $99 target By Investing.com - Investing.com South Africa
Judge Rules 5-Hour Energy Maker Gave Costco Unequal Deals, But No Antitrust Violation Found - PYMNTS.com
BTIG maintains Alcon stock Buy rating, $99 target - Investing.com
Turkey Contact Lens MarketCompetition, Forecast & Opportunities to 2030, Featuring Tech Contactlens, Diafarma, Alcon Laboratories, Diplomat Optics, Hoya Turkiye, ZEISS Turkiye, Keralens & more - Yahoo
U.S. Ophthalmic Photocoagulator Growth Trends and Forecasts 2025-2032 - GlobeNewswire Inc.
FTC Requests More Information on Alcon's $430 Million Acquisition of Lensar - PYMNTS.com
FTC Probing Alcon's $430M Lensar Deal - Law360
Stifel Nicolaus Reaffirms Their Buy Rating on Alcon (ALC) - The Globe and Mail
Eye care product makers Alcon, LENSAR get second request from US FTC - MLex
Alcon (ALC) Receives Upgrade to Buy from Kepler Cheuvreux | ALC Stock News - GuruFocus
Alcon Inc. (NYSE:ALC) Q1 2025 Earnings Call Transcript - MSN
Alcon (ALC): A Key Partner in Lifecore's Revenue Growth Strategy - GuruFocus
Alcon (ALC): A Key Partner in Lifecore's Revenue Growth Strategy | ALC Stock News - GuruFocus
Alcon (VTX:ALC) Strong Profits May Be Masking Some Underlying Issues - simplywall.st
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Alcon (ALC) - The Globe and Mail
Alcon's (VTX:ALC) Profits May Not Reveal Underlying Issues - Yahoo Finance
RBC cuts Alcon stock price target to CHF95, keeps Outperform rating - Investing.com Canada
RBC Capital Adjusts Price Target for Alcon (ALC) While Maintaining Optimism | ALC Stock News - GuruFocus
Stifel maintains Alcon stock Buy rating, $100 target amid new drug launch - Investing.com Nigeria
Deutsche Bank Downgrades Alcon (ALC) Rating, Lowers Price Target | ALC Stock News - GuruFocus
Deutsche Bank cuts Alcon stock rating, lowers price target - Investing.com
Deutsche Bank cuts Alcon stock rating, lowers price target By Investing.com - Investing.com Nigeria
RBC cuts Alcon stock price target to CHF95, keeps Outperform rating By Investing.com - Investing.com South Africa
LENSAR Announces Merger with Alcon Research - TipRanks
Alcon updates 2025 sales growth target to 6%-7% driven by new product launches and tariff mitigation - MSN
Alcon stock target cut to $109 by Bernstein on Q2 outlook - Investing.com Nigeria
Alcon’s Earnings Call: Balancing Growth and Challenges - TipRanks
Alcon (ALC) Sees Notable Increase in Borrow Rate | ALC Stock New - GuruFocus
Alcon Inc Stock (ALC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.13%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):